Cohero Health develops connected care devices and mobile and web applications under its BreatheSmart platform to engage respiratory patients, track medication adherence, and measure lung function. Its product suite includes wireless inhaler sensors, an FDA-cleared mobile spirometer, patient-facing mobile apps with reminders and rewards, and HIPAA-compliant web access for custom data. The company is building a large dataset of respiratory patient demographics, medication utilization, symptoms, pulmonary function, outcomes and costs. Cohero has deployed its platform across more than 25 commercial partnerships, representing over 1 million pediatric and adult asthma, COPD, and cystic fibrosis patients. Led by co-founder and CEO Melissa Manice, PhD, and co-founder and COO Dan Weinstein, the company is a member of StartUp Health, Springboard Enterprises, and Grand Central Tech. It plans to use new funding to grow commercial business development, expand its clinical trial program, and further evolve the BreatheSmart platform. Cohero Health develops connected devices and mobile applications aimed at engaging and empowering respiratory patients by measuring lung function and tracking adherence. Its proprietary platform includes wireless medication inhaler sensors, an FDA-cleared mobile spirometer, patient-facing mobile apps that generate reminders and reward compliance, and HIPAA-compliant servers for custom data access. The company is led by Melissa Manice, PhD, and is a member of StartUp Health, Springboard Enterprises, and Grand Central Tech. Cohero closed a $2M seed funding round to support scaling and commercialization. The company plans to use the funds to scale production of its devices for large customer deployments and to support the full-scale commercial launch of its platform. No operating metrics (revenue/users) were disclosed in the sourced article.

Total raised

$11M

Funding rounds

2

Latest round

Series A

Latest activity

Nov 2016